At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 241–250 of 615 results.
-
Researchers in this study want to compare sentinel lymph node biopsy surgery with standard neck dissection as part of the treatment for people with early-stage oral cavity (mouth) cancer. Sentinel lymph node biopsy is a procedure that removes a smaller number of lymph nodes from the neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard elective neck dissection removes many of the lymph nodes in the neck but may reduce shoulder mobility and strength.
-
Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.
-
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
-
Limited metastatic colorectal cancer is cancer that has spread to no more than 4 parts of the body. The usual treatment for limited metastatic colorectal cancer is chemotherapy. In this study, researchers want to see if adding local therapies makes treatment work better. Local therapies are used to treat cancer only at specific sites.
-
The purpose of this study is to assess the safety and effectiveness of adding the drug evexomostat (SDX-7320) to standard eribulin chemotherapy in people with triple-negative breast cancer (TNBC) that has come back or spread despite treatment. In addition, the participants in this study have metabolic disorders such as high blood sugar and/or obesity. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
-
The purpose of this study is to assess the feasibility of a new approach to treat people with T4 breast cancer who have already received chemotherapy. T4 breast cancer occurs when the cancer has grown beyond normal breast tissue and into the chest wall or skin or has become swollen and causes pain. Doctors normally treat T4 breast cancer with chemotherapy followed by mastectomy and removal of underarm (axillary) lymph nodes. After mastectomy, patients normally receive radiation therapy and then have breast reconstruction surgery many months to years after completing radiotherapy.
-
Researchers are seeking the best dose of cirtuvivint to use alone and with ASTX727 for leukemia and myelodysplastic syndromes (MDS). The people in this study have acute myeloid leukemia (AML) or MDS that keeps growing after treatment.
-
Researchers want to find the best dose of 225Ac-ABD147 to treat advanced lung cancer. The people in this study have small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma of the lung (LCNEC). Their cancer keeps growing even after treatment that included platinum-based chemotherapy.
-
The usual treatment for brain metastases (cancer that spread to the brain) is a single treatment of stereotactic radiosurgery (SRS). SRS uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor.
-
In this study, researchers want to see if enzalutamide, alone or with mifepristone, works well against advanced breast cancer. The people in this study have either triple-negative breast cancer (TNBC) or cancer that is low in estrogen receptors (ER). Receptors are docking sites on cancer cells for hormones or other proteins. TNBC is breast cancer that is not fueled by estrogen or progesterone and does not make a protein called HER2. The people in this study also have cancer cells that have receptors for proteins called androgens (AR-positive cancers).